Last reviewed · How we verify

Burkitt cell leukemia — Treatment Landscape & Competitive Intelligence

Burkitt cell leukemia (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Burkitt cell leukemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Mabthera rituxan Roche CD20-directed Cytolytic Antibody B-lymphocyte antigen CD20 1997-01-01
Mabthera Rituximab-Pvvr Roche Monoclonal antibody CD20 antigen on pre-B and mature B-lymphocytes 1997-01-01
Mabthera rituximab Roche CD20-directed Cytolytic Antibody [EPC] B-lymphocyte antigen CD20 1997-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Roche · 3 drugs in Burkitt cell leukemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Burkitt cell leukemia:

Cite this brief

Drug Landscape (2026). Burkitt cell leukemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/burkitt-cell-leukemia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing